... so that physicians can deliver a treatment that is tailored to the specific type of asthma or COPD found in that patient."
Deciphering these unique immune pathways also can identify new targets for ...
... function and the number of other illnesses they had.”
The researchers anticipated that those with end-stage COPD would be more ill with lung or other diseases. “Previous work has taught us that even ...
... to GOLD/ATS guidelines, a written action plan that included a description of symptoms of COPD exacerbations, and refillable prescriptions for antibiotics and or short courses of prednisone to manage ...
... optimize the results of pulmonary rehabilitation, we had to appreciate that only a small portion of patients with COPD actually engage in pulmonary rehabilitation….so improved [access] is important ...
... of decline in FEV1," remarked Dr. Celli. This is the first demonstration of an effective pharmacothrerapy in COPD.
The TORCH study randomized more than 6,000 patients with moderate to severe COPD ...
... and ipratropium bromide, made and marketed by Boehringer Ingelheim as Atrovent™.
"Patients with COPD who use these inhalers are at a high risk of excess serious cardiovascular events due to their ...
... for patients who are at high risk for or who have known cardiovascular disease.
But patients with COPD, who have an increased risk of cardiovascular disease, often do not receive preoperative beta- ...
... of beta-blockers on surgical patients with chronic obstructive pulmonary disease (COPD), researchers have found that, contrary to previous thought, beta-blockers significantly reduce mortality in ...
... in follow up, because patients who withdrew earlier had more severe COPD and were more depressed than those who completed follow-up, it is likely that the association was underestimated than anything ...
... year-long randomized, double-blind, placebo-controlled study of the effects of erythromycin in COPD. The results were published in the first issue for December of the American Journal of Respiratory ...
... . While the results of our subgroup analysis suggest the existence of subpopulations of patients with COPD who might be at higher risk for pneumonia, our evidence is not conclusive and is only ...
... available to improve shortness of breath, effort tolerance and the quality of life of patients suffering from COPD. "Our results prove that home-based rehabilitation is just as effective and safe as ...
... ) -- Men across the Asia-Pacific region have consistently higher mortality and hospitalization rates for chronic obstructive pulmonary disease (COPD) than corresponding rates for women in the region.
... marketed by AstraZeneca as SymbicortTM.
The inhalers are effective in relieving many of the symptoms of COPD, but have been associated with an increased risk of pneumonia in recent studies.
For the ...
... .
To test the validity of this assumption, which not only informs treatment plans for patients with COPD, but also forms the basis of research design and analysis, Dr. Hurst and colleagues analyzed ...
